HIGHLIGHTS
- who: Kieran J. Moore and colleagues from the Department of Urology, Queen Elizabeth II Health Sciences Center, Dalhousie University have published the Article: Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis, in the Journal: (JOURNAL)
SUMMARY
The standard chemotherapy for treatment of poor risk patients is four cycles of bleomycin, etoposide, and cisplatin (BEP) or etoposide, ifosfamide, and cisplatin (VIP). The patient as an inpatient consisting of dose Cis‐ 2 and Etoposide 60 mg/m2 (60% dose) days 1 to 5 every 21 Cisplatin 20 mg/m was platin . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.